Illumina, Inc. $ILMN Stock Holdings Lowered by Letko Brosseau & Associates Inc.

Letko Brosseau & Associates Inc. lessened its stake in Illumina, Inc. (NASDAQ:ILMN) by 3.2% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 803,843 shares of the life sciences company’s stock after selling 26,450 shares during the quarter. Illumina comprises 2.8% of Letko Brosseau & Associates Inc.’s holdings, making the stock its 9th largest position. Letko Brosseau & Associates Inc.’s holdings in Illumina were worth $219,996,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ILMN. BlackRock Inc. purchased a new stake in Illumina in the 2nd quarter valued at about $3,374,423,000. Primecap Management Co. CA purchased a new position in shares of Illumina during the second quarter worth approximately $617,981,000. Jupiter Topco LLC purchased a new position in shares of Illumina during the second quarter worth approximately $358,652,000. WCM Investment Management LLC increased its position in shares of Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after acquiring an additional 1,851,848 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in shares of Illumina during the second quarter valued at approximately $293,846,000. Institutional investors own 89.42% of the company’s stock.

Insider Buying and Selling at Illumina

In related news, Director Keith Meister sold 299,336 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $217.96, for a total transaction of $65,243,274.56. Following the completion of the transaction, the director owned 1,409,851 shares of the company’s stock, valued at approximately $307,291,123.96. This trade represents a 17.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 1,881,899 shares of company stock worth $415,905,954. Company insiders own 2.90% of the company’s stock.

Illumina Trading Down 1.6%

ILMN opened at $209.55 on Friday. The stock has a market capitalization of $31.68 billion, a PE ratio of 40.56, a P/E/G ratio of 2.89 and a beta of 1.46. Illumina, Inc. has a one year low of $112.65 and a one year high of $309.35. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.05 and a current ratio of 2.63. The business’s 50 day moving average price is $249.32 and its 200 day moving average price is $179.36.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.26. The company had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.15 billion. Illumina had a net margin of 19.72% and a return on equity of 28.38%. Illumina’s revenue was up 4.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.34 earnings per share. As a group, equities research analysts expect that Illumina, Inc. will post 5.43 EPS for the current year.

Top Illumina Stories

Investors following ILMN have been watching these stories:

• Positive Sentiment: Illumina reported third-quarter revenue of $1.129 billion and net income of $220 million, raised its 2026 revenue outlook to $4.64 billion–$4.66 billion, and highlighted strength in clinical sequencing consumables. How Investors May Respond To Illumina (ILMN) Earnings Beat
• Positive Sentiment: The company expanded its molecular residual disease research portfolio with an ultrasensitive duplex sequencing workflow for circulating tumor DNA and was selected to provide whole-genome sequencing services for Singapore’s SG-INSIGHT precision-medicine study. These developments support its push into clinical oncology and sequencing applications. Illumina (ILMN) Unveils Duplex Sequencing Workflow For MRD Research
• Negative Sentiment: Director Keith Meister sold 280,091 shares over November 9–11 for approximately $61.1 million, reducing his direct holdings to 208,826 shares. The scale of the sales could raise concerns among investors, despite his continuing substantial ownership. SEC filing

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ILMN. UBS Group upgraded Illumina from a “neutral” rating to a “buy” rating and boosted their price target for the company from $135.00 to $260.00 in a report on Wednesday, September 9th. Evercore restated an “underperform” rating on shares of Illumina in a report on Friday, October 30th. JPMorgan Chase & Co. decreased their target price on Illumina from $320.00 to $300.00 and set an “overweight” rating for the company in a research report on Friday, October 30th. Wall Street Zen lowered Illumina from a “buy” rating to a “hold” rating in a research report on Saturday, November 7th. Finally, Sanford C. Bernstein reiterated a “market perform” rating and issued a $215.00 target price on shares of Illumina in a report on Friday, July 31st. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $244.24.

About Illumina

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.